Safety study of adjuvant therapy using alpha fetoprotein derived peptide after transarterial chemoembolization for hepatocellular carcinoma
Not Applicable
- Conditions
- hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000029412
- Lead Sponsor
- Kanazawa University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 8
Inclusion Criteria
Not provided
Exclusion Criteria
1) Refractory ascites or pleural effusion 2) History of hepatic encephalopathy within 3 months 3) Risky varices 4) Active double cancer 5) Transfusion of RCC, PC, FFP, or G-CSF within 2 weeks 6) Administration of steroid or immuno suppressive agents 7) Severe complication 8) Systemic infection (excluded viral hepatitis) 9) Pregnant or lactating women, or women of childbearing potential 10) Mental disorder 11) Allergy for AFP derived peptides or adjuvant 12) Allergy for contrast agent of CT or/and MRI 13) Inappropriate candidate for this study judged by doctor in charge
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severe adverse events
- Secondary Outcome Measures
Name Time Method